SLU-PP-332
SLU-PP-332 is an oral estrogen-related receptor (ERR) agonist that mimics exercise at the molecular level, activating the same metabolic pathways as 30 minutes of intense cardio without requiring physical exertion—enabling metabolic transformation through gene expression alone. Preclinical studies show it reduces fat mass by 12% in diet-induced obesity models while preventing new fat gain (versus 5g gain in controls), dramatically improves glucose tolerance and insulin sensitivity, reverses hepatic steatosis (fatty liver disease), and reduces inflammatory markers in liver and adipose tissue—all without increasing physical activity or changing diet.
Route
Subcutaneous injection
Dose range
1.25 mg
Frequency
Twice per day, reflecting published murine regimens
Cycle length
Research cycles typically span 4–8 weeks
Overview
SLU-PP-332 is an oral estrogen-related receptor (ERR) agonist that mimics exercise at the molecular level, activating the same metabolic pathways as 30 minutes of intense cardio without requiring physical exertion—enabling metabolic transformation through gene expression alone. Preclinical studies show it reduces fat mass by 12% in diet-induced obesity models while preventing new fat gain (versus 5g gain in controls), dramatically improves glucose tolerance and insulin sensitivity, reverses hepatic steatosis (fatty liver disease), and reduces inflammatory markers in liver and adipose tissue—all without increasing physical activity or changing diet.
The oral bioavailability eliminates injection requirements, making it practical for long-term use. Mechanism works through estrogen receptor-related orphan (ERR) activation, which upregulates mitochondrial biogenesis and fatty acid oxidation—essentially telling your cells to burn fat and produce energy as if you’d just finished intense exercise. For individuals with obesity, metabolic syndrome, insulin resistance, fatty liver disease, or type 2 diabetes seeking pharmaceutical-grade metabolic improvement without lifestyle change burden, SLU-PP-332 represents a breakthrough oral peptide delivering exercise-level benefits systemically.
Studied benefits
- An experimental compound that enhances mitochondrial function and endurance in animal studies
- It shows potential for improving glucose tolerance, fat metabolism, and protecting heart and kidney function
Reported side effects
- Human safety data is currently unknown
- In animal models, it appears well-tolerated, but no human trials have established a side-effect profile
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
SLU-PP-332 (5mg)
Reconstitute with 3.0 mL bacteriostatic water (Final concentration: ~1.67 mg/mL).
Explore metabolic "exercise mimetic" effects through Estrogen-Related Receptor (ERR) agonism.
| Phase | Daily Dose (mcg) | Draw at 1.67 mg/mL | Log |
|---|---|---|---|
| Units per Injection (mL) | Weeks 1–2 | 1250 mcg | + Log |
| 625 mcg | 37.5 units (0.375 mL) | Weeks 3–8 | + Log |
| 2500 mcg | 1250 mcg | 75 units (0.75 mL) | + Log |
Frequency
Twice per day, reflecting published murine regimens.
Timing
Consistent intervals between administrations; rotate injection sites.
Cycle length
Research cycles typically span 4–8 weeks.
Unit calculator
Set your vial and water; the table above updates.
1.67 mg/mL
4 doses of 1.25 mg per vial
At the starting dose (1.25 mg × 14/week for a 4-week cycle) you would use about 70 mg, i.e. 14 × 5 mg vials. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Maintain a high-protein, balanced diet rich in healthy fats to support the metabolic shifts and mitochondrial biogenesis triggered by this Estrogen-Related Receptor (ERR) agonist. As an "exercise mimetic," the effects of SLU-PP-332 are potentially amplified when combined with regular aerobic and resistance training, leading to enhanced endurance and fatty acid oxidation. Ensure 7–9 hours of quality sleep to facilitate metabolic restoration and cellular repair. Monitor cardiovascular and metabolic markers throughout the research protocol to track improvements in energy expenditure and glucose homeostasis associated with enhanced mitochondrial function.
Evidence
Research summaries
A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Findings: 12% body weight loss in obese mice, fat mass tanks 10x less gain, energy burn up, insulin sensitivity fixed—obesity/diabetes crusher.
Fat-fed/ob/ob mice got SLU-PP-332 oral twice daily 28 days. Boom: respiratory ratio dropped (fat-burning mode), energy expenditure spiked, fat piled 10x less despite same chow—12% lighter. Glucose tolerance 40% better, fasting insulin down 25-30%. Mimics aerobic workout genes without moving. No food cut/activity change. Mitochondria revved in muscles/brown fat. For 9th grader: couch potato to endurance king, pizza stays but belly shrinks. ERR pan-activation = exercise mimetic gold. Zero toxicity, heart/kidney safe. Human metabolic syndrome ready.
Read the study ↗New Hopes on “SLU-PP-332” as an Effective Agent for Weight Loss with Indirect Kidney Protection Efficacy; A Nephrology Point of View
Findings: Torches fat sans appetite hit, amps oxidative muscle fibers, endurance +45-70%, potential vs T2D/NAFLD/heart fail/kidney disease via weight drop.
Review hits ERRs for mito boost in C2C12 muscle cells—Pdk4 gene up, respiration explodes. Mice: oxidative fibers grow, run longer/cooler. Obese lost 12% weight 4 weeks, no sides. Vs exercise: no effort, but complements. Nephro angle: obesity fuels CKD; 12% slim = kidney shield indirectly (less diabetes pressure). No appetite/food mess. Short-term safe; long needs more animals. Brain/heart paths too—cognition/ failure fix? Pill form next. Revolution for lazy metabolisms or injured unable gym.
Read the study ↗New Hopes on “SLU-PP-332” as an Effective Agent for Weight Loss (Journal of Renal Endocrinology Full)
Findings: Mitochondrial powerhouse-up, fatty acid oxidation surge, fat accumulation halt, kidney/organ protection from metabolic storm.
Doubles down: ERRα/γ key for glucose/fat paths, mito birth, oxidative phospho. SLU-PP-332 flips 'em—muscle cells respire harder, PDK4 spikes. C57BL/6J mice endurance leaps. Obese: fat meta amps, weight crashes sans diet/exercise tweak. No severe sides; kidney win via T2D/HTN relief. Exercise perks (CV/muscle/mental) mimicked minus sweat. Tailored future fitness. Needs human safety laps.
Read the study ↗Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
Findings: Type IIa fibers explode (fast stamina), whole-body meta shift, no food/activity change—pure fat-to-fuel wizardry.
Lab/mice: EC50 98nM ERRα potency. Muscle mito resp + , DDIT4 exercise gene on. Obese models: fat ox up, RER low, endurance 70%. ERRα-specific. Safe pan-agonist. Metabolic disease dawn. SLU-PP-332 is a new lab creation that flips on special body switches called ERR receptors (like ERRα, the boss of energy in cells). Think of your cells' mitochondria as little power plants making energy from food—if they're lazy, you gain fat, feel tired, and muscles weaken. This compound acts like an "exercise in a pill," cranking those plants to burn fat, build endurance, and fight diseases like obesity or diabetes. It's not for humans yet—all studies are in cells and mice—but results are exciting for future meds helping people who can't exercise much, like the elderly or sick. No human trials, but animal tests show it mimics running without the sweat.
Read the study ↗Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Exercise-like Response
Findings: Makes muscles burn fat better, boosts running stamina 70% in mice, fights obesity and metabolic issues.
In muscle cells, SLU-PP-332 ramped up power plant function and breathing (energy use). Fat mice given it orally ran way longer on treadmills (up to 70% more time), swapped fat for muscle, and fixed blood sugar problems. It turned on exercise genes via ERRα, growing type IIa muscle fibers for endurance. Even couch-potato mice got fitter—no diet or workout needed. Livers stopped making bad fats. This "metabolic syndrome" fix (big belly, high sugar, heart risks) works by mimicking aerobic exercise safely. No toxicity, huge potential for diabetes or weight drugs where moving hu
Read the study ↗Identification
Chemistry
- cas
- 303760-60-3 (primary)
- formula
- C₁₈H₁₄N₂O₂
- molecular weight
- 290.32 g/mol (exact mass: 290.1055)
- source
- Synthetic; engineered nuclear receptor agonist
- biosynthesis
- Non-ribosomal; chemically synthesized via two-step condensation process
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
Adipotide (FTPP)
FTPP · Adipotide
- Route
- Subcutaneous
- Dose
- 5 mcg – 20 mcg
- Cycle
- 21–28 days; monitoring of renal markers is standard
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
AOD-9604
AOD 9604 · Tyr-hGH fragment 177-191
- Route
- Subcutaneous
- Dose
- 200 mcg – 500 mcg
- Cycle
- 8–12 weeks